The Technology Research Platform VirNext is a spin-off (EZUS Lyon) of the Université Claude Bernard Lyon 1 (UCBL1), which was created within the VirPath laboratory to foster industrial partnerships and enhance translational research. VirNext offers expertise in the field of respiratory viruses (including SARS-CoV-2) and provides a large panel of technologies, including egg and cell-based processes of virus and vaccine antigen production, and several potency tests using in vitro (cell lines and reconstituted human airway epithelium) and in vivo models of infections dedicated to the evaluation of prophylactic and therapeutic candidates.